Multicomponent therapeutics for networked systems
The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Therapeutic regimens that comprise more than one active ingredient are commonly used in clinical medicine. Despite this, most drug discovery efforts search for drugs that are composed of a single chemical entity. A focus in the early drug discovery process on identifying and optimizing the activity of combinations of molecules can result in the identification of more effective drug regimens. A systems perspective facilitates an understanding of the mechanism of action of such drug combinations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“combinations of chemical agents (or manipulations such as those of transcription factors that affect multiple steps in a pathway [1906] or modulation of multiple gene products [2311], or both [2312,2313]) will be far more efficacious, for instance in modulating iron-catalysed oxidative stress and its sequelae, than will be the use of 'magic bullet' single agents.”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1705]
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“There have been attempts to systematize a set of principles that can account for combination drugs that exist toda”
BackgroundLessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Systems biology: a brief overview
Kitano, H. (2002) · Science · doi:10.1126/science.1069492 · Cited by 4,265 · cited 1×
“Systems biology is the large-scale study of the functional and physical relationships between the molecules that make up lif”
BackgroundBlume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Transcriptional Regulatory Networks in Saccharomyces cerevisiae
Lee, T. I., Rinaldi, N. J., Robert, F., Odom, D. T., Bar-Joseph, Z., Gerber, G. K., Hannett, N. M., Harbison, C. T., Thompson, C. M., Simon, I., et al. (2002) · Science · doi:10.1126/science.1075090 · Cited by 2,956
THE TOXICITY OF POISONS APPLIED JOINTLY1
BLISS, C. I. (1939) · Annals of Applied Biology · doi:10.1111/j.1744-7348.1939.tb06990.x · Cited by 2,419 · cited 1×
“Numerous researchers have attempted to provide an unambiguous framework for the calculation of additive effects between compounds; these approaches are reviewed comprehensively elsewher”
BackgroundSystematic Genetic Analysis with Ordered Arrays of Yeast Deletion Mutants
Tong, A. H. Y., Evangelista, M., Parsons, A. B., Xu, H., Bader, G. D., Pagé, N., Robinson, M., Raghibizadeh, S., Hogue, C. W. V., Bussey, H., et al. (2001) · Science · doi:10.1126/science.1065810 · Cited by 2,138
A N EW A PPROACH TO D ECODING L IFE : Systems Biology
Ideker, T., Galitski, T., & Hood, L. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.343 · Cited by 1,664 · cited 1×
“Systems biology is the large-scale study of the functional and physical relationships between the molecules that make up lif”
BackgroundDolma, S., Lessnick, S. L., Hahn, W. C., & Stockwell, B. R. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00050-3 · Cited by 1,446
Self-citation
Research works printed but not linked: 2
- Ehrlich, P. Chemotherapeutics: scientific principles, methods and results. Lancet 2, 445–451 (1913).
- Albert, A. Selective Toxicity (Methuen & Co., London, 1968).
Cited by
Items 201–300 of 799
Epigenetic regulation of diacylglycerol kinase alpha promotes radiation-induced fibrosis
Weigel, C., Veldwijk, M. R., Oakes, C. C., Seibold, P., Slynko, A., Liesenfeld, D. B., Rabionet, M., Hanke, S., Wenz, F. K., Sperk, E., et al. (2016) · Nature Communications · doi:10.1038/ncomms10893 · Cited by 68
Design, Synthesis and In Vitro Antiproliferative Activity of Novel Isatin‐Quinazoline Hybrids
Farès, M., Eldehna, W. M., Abou‐Seri, S. M., Abdel‐Aziz, H. A., Aly, M. H., & Tolba, M. F. (2015) · Archiv der Pharmazie · doi:10.1002/ardp.201400337 · Cited by 62
Audouze, K., Juncker, A. S., Roque, F. S., Krysiak-Baltyn, K., Weinhold, N., Taboureau, O., Jensen, T. S., & Brunak, S. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000788 · Cited by 63
“The mechanism of action of these small molecules is often not completely understood and can be associated to adverse and toxic effects through for example drug-drug interactions [6].”
BackgroundTekin, E., Beppler, C., White, C., Mao, Z., Savage, V. M., & Yeh, P. J. (2016) · Journal of The Royal Society Interface · doi:10.1098/rsif.2016.0332 · Cited by 71
Defining and characterizing drug/compound function
Kenakin, T., & Williams, M. J. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.033 · Cited by 69
Mukherjee, P. K., Banerjee, S., & Kar, A. (2021) · Phytochemistry Reviews · doi:10.1007/s11101-020-09730-4 · Cited by 69
Lipid‐Like Nanomaterials for Simultaneous Gene Expression and Silencing In Vivo
Dong, Y., Eltoukhy, A. A., Alabi, C. A., Khan, O. F., Veiseh, O., Dorkin, J. R., Sirirungruang, S., Yin, H., Tang, B. C., Pelet, J. M., et al. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201400054 · Cited by 60
Wang, S., Chen, R., Zhong, Z., Shi, Z., Chen, M., & Wang, Y. (2014) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x14500803 · Cited by 61
“Synergistic combination of two or more drugs is an effective strategy to access context-specific multiple targets and overcome undesirable toxicity or other side effects that are almost inevitable in single-drug chemotherapy, whose one-dimensional action mechanism often activates and strengthens the alternative pathwa…”
BackgroundJi, H.-F., Kong, D.-X., Shen, L., Chen, L.-L., Ma, B.-G., & Zhang, H.-Y. (2007) · Genome Biology · doi:10.1186/gb-2007-8-8-r176 · Cited by 59
Synergy in natural medicines: implications for drug discovery
Li, X., & Zhang, H. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.04.002 · Cited by 60
H., X., Wang, R., Tan, C., Jiang, Y., Lu, T., Rao, H., Li, X., Go, M., Low, B. C., & Chen, Y. (2010) · Molecular Pharmaceutics · doi:10.1021/mp100179t · Cited by 60
Kim, H., Kim, E., An, Y., Choi, J., Jang, E., Choi, E. B., Kukreja, A., Kim, M.-H., Kang, B., Kim, D., et al. (2013) · Macromolecular Bioscience · doi:10.1002/mabi.201200448 · Cited by 59
Hou, Y., Cao, X., Wang, L., Cheng, B., Dong, L., Luo, X., Bai, G., & Gao, W. (2012) · Journal of Chromatography B · doi:10.1016/j.jchromb.2012.10.004 · Cited by 62
Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity
Ho, Ho, Sánchez, Shahangian, Al-Shyoukh, & Cheng (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s27540 · Cited by 67
“7,8 11 Often, the studies used high dosages of individual drugs to ensure treatment efficacy.”
Gao, J., Fan, K., Jin, Y., Zhao, L., Wang, Q., Tang, Y., Xu, H., Liu, Z., Wang, S., Lin, J., et al. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105070 · Cited by 61
Alsherbiny, M. A., Bhuyan, D. J., Low, M., Chang, D., & Li, C. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810103 · Cited by 61
“Based on the anticancer actions of CBD, it has been suggested that combinations of CBD and chemotherapeutic drugs may overcome cancer resilience by targeting various cancers’ pathophysiological components [58,59].”
BackgroundSoo, J. S.-S., Ng, C., Tan, S. H., Malik, R. A., Teh, Y.-C., Tan, B.-S., Ho, G. F., See, M., Taib, N. A. M., Yip, C. H., et al. (2015) · APOPTOSIS · doi:10.1007/s10495-015-1158-5 · Cited by 65
Drosophila Cancer Models Identify Functional Differences between Ret Fusions
Levinson, S., & Cagan, R. L. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.019 · Cited by 58
“Recently, interest has risen in the use of drug combinations to improve efficacy and to overcome resistance (Al-Lazikani et al., 2012; Iadevaia et al., 2010; Keith et al., 2005; Shi et al., 2011; Yan et al., 2010).”
BackgroundTurning promiscuous kinase inhibitors into safer drugs
Zhang, X., Crespo, A., & Fernández, A. (2008) · Trends in biotechnology · doi:10.1016/j.tibtech.2008.02.008 · Cited by 58
RETRACTED: Decrypting the potential role of α-lipoic acid in Alzheimer's disease
Kaur, D., Behl, T., Sehgal, A., Singh, S., Sharma, N., Chigurupati, S., Alhowail, A., Abdeen, A., Ibrahim, S. F., Vargas-De-La-Cruz, C. B., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119899 · Cited by 59
RetractedUnconventional screening approaches for antibiotic discovery
Farha, M. A., & Brown, E. D. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12803 · Cited by 60
Bianchi, M. T., Pathmanathan, J. S., & Cash, S. S. (2008) · Medical Hypotheses · doi:10.1016/j.mehy.2008.09.049 · Cited by 59
“An extension of the idea of single-agent poly-pharmacy is the recent interest in combinatorial therapeutics [41–43].”
BackgroundUncovering Scaling Laws to Infer Multidrug Response of Resistant Microbes and Cancer Cells
Wood, K. B., Wood, K. C., Nishida, S., & Cluzel, P. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.007 · Cited by 61
“Multidrug therapies can be difficult to design because drugs often interact, making their combined effects larger or smaller than expected from their individual effects (Bliss, 1956; Fitzgerald et al., 2006; Greco et al., 1995; Keith et al., 2005; Lehár et al., 2008; Loewe, 1953).”
Small molecules with anti-inflammatory properties in clinical development
Hanke, T., Merk, D., Steinhilber, D., Geißlinger, G., & Schubert‐Zsilavecz, M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.011 · Cited by 59
Guo, X. D., Shen, L. H., Tong, Y., Zhang, J., Wu, G., He, Q., Yu, S., Ye, X., Zou, L., Zhang, Z., et al. (2013) · Phytomedicine · doi:10.1016/j.phymed.2013.04.002 · Cited by 55
Su, J., Zhang, L., Zhang, W., Choi, D. S., Wen, J., Jiang, B., Chang, C.-C., & Zhou, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085059 · Cited by 57
“Loewe combination index [37,38] (for an introduction and a guide of interpretation of Loewe combination index please refer to Figure S1 in the Supporting Information), defined according to the 50% MIC population reduction by the end of the two week chemotherapy (E50 at time point 600 hr), was utilized to evaluate the…”
MethodEmergence and natural selection of drug-resistant prions
Shorter, J. (2010) · Molecular BioSystems · doi:10.1039/c004550k · Cited by 60
Compromised in vitro dissolution and membrane transport of multidrug amorphous formulations
Alhalaweh, A., Bergström, C. A. S., & Taylor, L. S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.03.028 · Cited by 55
Zheng, M., Zhao, J., Cui, C., Fu, Z., Li, X., Liu, X., Ding, X., Tan, X., Li, F., Luo, X., et al. (2018) · Medicinal Research Reviews · doi:10.1002/med.21483 · Cited by 59
“189 Many statistical learning algorithms have been used in drug-combination discovery.”
MethodZimmermann, G. R., Avery, W., Finelli, A. L., Farwell, M., Fraser, C. C., & Borisy, A. A. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2602 · Cited by 55
“An alternative approach to dissociation makes use of synergistic multi-target biology to amplify selectively the anti-inflammatory activity of glucocorticoids in immune cells without affecting glucocorticoid-induced adverse effects in alternative cellular networks [22,23].”
BackgroundSelf-citationYoussif, B. G. M., Gouda, A. M., Moustafa, A. H., Abdelhamid, A. A., Gomaa, H. A. M., Kamal, I., & Marzouk, A. A. E. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.132218 · Cited by 57
Huang, T. H.-W., Tran, V. H., Roufogalis, B. D., & Li, Y. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.03.013 · Cited by 54
A novel anti-Alzheimer's disease drug, ladostigil
Weinreb, O., Amit, T., Bar‐Am, O., & Youdim, M. B. H. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-386467-3.00010-8 · Cited by 60
He, W., Yan, J., Sui, F., Wang, S., Su, X., Qu, Y., Yang, Q., Guo, H., Ji, M., Lu, W., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b07079 · Cited by 54
Hiss, D. C., Gabriels, G. A., & Folb, P. I. (2007) · Cancer Cell International · doi:10.1186/1475-2867-7-5 · Cited by 61
Park, H., Lee, J., Lim, J., & Kang, B. H. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-148 · Cited by 53
“Multicomponent and system-oriented therapeutics development approaches could provide a solution [60,61].”
Discovery of antibiotic adjuvants
Farha, M. A., & Brown, E. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2500 · Cited by 52
Weinreb, O., Mandel, S. A., Bar‐Am, O., & Amit, T. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0597-6 · Cited by 53
Sezin, T., Murthy, S., Attah, C., Seutter, M., Holtsche, M. M., Hammers, C. M., Schmidt, E., Meshrkey, F., Mousavi, S., Zillikens, D., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128239 · Cited by 51
Novotný, M. V., Soini, H. A., & Mechref, Y. S. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2007.10.007 · Cited by 59
Xu, Q., Cheng, M., Jiang, R., Zhao, X., Zhu, J., Liu, M., Chao, X., Zhang, C., & Zhou, B. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.971647 · Cited by 52
“Furthermore, the factors influencing the production performance of weaning pigs are complex, so the effect of a single herbal medicine is often limited in the treatment of these complicated problems caused by weaning stress (17).”
BackgroundPRMT1 inhibition promotes ferroptosis sensitivity via ACSL1 upregulation in acute myeloid leukemia
Zhou, L., Jia, X., Shang, Y., Sun, Y., Liu, Z., Liu, J., Jiang, W., Deng, S., Yao, Q., Chen, J., et al. (2023) · Molecular Carcinogenesis · doi:10.1002/mc.23550 · Cited by 53
“To determine whether the effects were synergistic, we calculated the synergy scores of the GSK3368715 and RSL3 combination using the Bliss independent model.(34,35) If the actual cell viability was less than, equal to, or greater than the predicted value, the effect was classified as synergistic, additive, or antagoni…”
MethodShah, N. A., Laws, R. J., Wardman, B., Zhao, L. P., & Hartman, J. L. (2007) · BMC Systems Biology · doi:10.1186/1752-0509-1-3 · Cited by 52
“On a smaller scale, quantitative analysis of gene interactions has proven advantageous by virtue of being more objective, sensitive, and discriminating between strength of interactions, which can aid identification of distinct pathways represented within large sets of interacting genes [2,11-14].”
BackgroundPourkavoos, N. (2012) · Combination Products in Therapy · doi:10.1007/s13556-012-0002-2 · Cited by 52
“Combination products range from drug-drug combinations [1, 2], drug-device combinations such as drug-eluting stents for coronary blockages, and drug-biological product such as monoclonal antibodies combined with a chemotherapy agent for cancer treatment [3–5].”
BackgroundNeomycin Sulfate Improves the Antimicrobial Activity of Mupirocin-Based Antibacterial Ointments
Blanchard, C. E., Brooks, L. R., Beckley, A., Colquhoun, J. M., Dewhurst, S., & Dunman, P. M. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02083-15 · Cited by 53
“Drug combinations are a mainstay therapeutic strategy in the treatment of cancer, HIV, asthma, hypercholesterolemia, malaria, and tuberculosis (61).”
BackgroundSynthesis and Biological Evaluation of Caffeic Acid 3,4-Dihydroxyphenethyl Ester
Zhang, Z., Xiao, B., Chen, Q., & Lian, X. (2010) · Journal of Natural Products · doi:10.1021/np900519d · Cited by 52
Kholodenko, B. N. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.014 · Cited by 49
“Interactions between two inhibitors or drugs also can be assessed by plotting inhibition effects across a two-dimensional range of drug doses, thereby creating a response surface (Keith et al., 2005; Yeh et al., 2009).”
BackgroundZullo, K. M., Guo, Y., Cooke, L. S., Jirau-Serrano, X., Mangone, M. A., Scotto, L., Amengual, J. E., Mao, Y., Nandakumar, R., Cremers, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0033 · Cited by 50
“Synergistic interactions were measured using excess over bliss (EOB) as previously described (16-18).”
MethodSzczepańska, K., Podlewska, S., Dichiara, M., Gentile, D., Patamia, V., Rosier, N., Mönnich, D., Ruiz‐Cantero, M. C., Karcz, T. P., Łażewska, D., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00435 · Cited by 51
Obbo, C. J. D., Kariuki, S. T., Gathirwa, J. W., Olaho-Mukani, W., Cheplogoi, P. K., & Mwangi, E. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.09.029 · Cited by 48
Xiang, L., Jiang, P., Zhan, C., Chen, Z., Liu, X., Huang, X., Wang, S., Hu, Y., Zhang, W., & Liu, R. (2012) · Molecular BioSystems · doi:10.1039/c2mb25172h · Cited by 50
Current Methods for Quantifying Drug Synergism.
Ma, J., & Motsinger‐Reif, A. A. (2019) · PubMed · Cited by 66
Charting protein complexes, signaling pathways, and networks in the immune system
Bauch, A., & Superti‐Furga, G. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00369.x · Cited by 51
“In the future, a detailed elucidation of the pathway logic may assist in providing a molecular reason for the synergistic effects and for combination therapy (120).”
BackgroundGarcía, E., Coa, J. C., Otero, E., Cardá, M., Vélez, I. D., Robledo, S. M., & Cardona‐Galeano, W. (2017) · Medicinal Chemistry Research · doi:10.1007/s00044-017-2076-6 · Cited by 47
“In recent years, a promising strategy has emerged based on hybrid molecules which bear in their structures two distinct pharmacophores having, for example, antiprotozoal, anti-inflammatory, antifungal, or anticancer activity, and thus showing a dual mode of action (Keith et al. 2005; Meunier 2008).”
BackgroundWang, Y., Sun, Y., Wang, Y., Ju, Y., & Meng, D. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102924 · Cited by 47
Drug discovery enters a new era with multi-target intervention strategy
Tian, X.-Y., & Liu, L. (2012) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-011-0900-2 · Cited by 47
Taha, M., Ismail, N. H., Imran, S., Selvaraj, M., Rahim, A., Ali, M., Siddiqui, S., Rahim, F., & Khan, K. M. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.10.037 · Cited by 46
Otero, E., Vergara, S., Robledo, S. M., Cardona, W., Cardá, M., Vélez, I. D., Rojas, C. A., & Otálvaro, F. (2014) · Molecules · doi:10.3390/molecules190913251 · Cited by 46
“The combination of two pharmacological agents into a single molecule, called hybrid molecule, is an emerging strategy in medicinal chemistry and drug discovery research [28,29].”
BackgroundDrug discovery and computational strategies in the multitarget drugs era
Viana, J. D. O., Félix, M. B., Maia, M. D. S., Serafim, V. D. L., Scotti, L., & Scotti, M. T. (2018) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902018000001010 · Cited by 48
Li, J., Liu, H., Yang, Z., Yu, Q., Zhao, L., & Wang, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.622787 · Cited by 50
Straube, A. M., Aicher, B., Fiebich, B. L., & Haag, G. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-43 · Cited by 50
“It is now time to revisit past experiences to identify multicomponent therapeutics for the treatment of complex diseases [8].”
BackgroundInfluentialJain, S., Jain, R., Das, M., Agrawal, A. K., Thanki, K., & Kushwah, V. (2014) · RSC Advances · doi:10.1039/c4ra04237a · Cited by 45
Djuidje, E. N., Barbari, R., Baldisserotto, A., Durini, E., Sciabica, S., Balzarini, J. M., Liekens, S., Vertuani, S., & Manfredini, S. (2022) · Antioxidants · doi:10.3390/antiox11020407 · Cited by 50
Metabolic reconstruction and analysis for parasite genomes
Pinney, J. W., Papp, B., Hyland, C. J. T., Wambua, L., Westhead, D. R., & McConkey, G. A. (2007) · Trends in Parasitology · doi:10.1016/j.pt.2007.08.013 · Cited by 50
Bifunctional Lipocalin Ameliorates Murine Immune Complex-induced Acute Lung Injury
Roversi, P., Ryffel, B., Togbe, D., Maillet, I., Teixeira, M. M., Ahmat, N., Paesen, G. C., Lissina, O., Boland, W., Ploss, K., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.420331 · Cited by 44
“Possible advantages of targeting more than one pathway include higher specificity, lower effective dose (1), and the ability to counteract compensation mechanisms within biological networks (2, 3).”
BackgroundKobayashi, T., Koizumi, Y., Takeuchi, J. S., Misawa, N., Kimura, Y., Morita, S., Aihara, K., Koyanagi, Y., Iwami, S., & Sato, K. (2014) · Journal of Virology · doi:10.1128/jvi.00062-14 · Cited by 44
“Here, we estimated the combination of each antiviral effect by Bliss independence, which is a major index for the evaluation of drug combination effects (41, 42).”
BackgroundHu, J., Wu, Z., Yan, J., Pang, W., Liang, D., & Xu, X. (2009) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2009.03.007 · Cited by 45
Danafar, H., Sharafi, A., Kheiri, S., & Manjili, H. K. (2018) · PubMed Central · Cited by 44
Network-principled deep generative models for designing drug combinations as graph sets
Karimi, M., Hasanzadeh, A., & Shen, Y. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btaa317 · Cited by 45
“Considering that most diseases and their resistances are multifactorial (Kaplan and Junien, 2000; Keith et al., 2005), multiple drugs targeting multiple components simultaneously could confer less resistance than individual drugs targeting components separately.”
BackgroundFimognari, C., Lenzi, M., Ferruzzi, L., Turrini, E., Scartezzini, P., Poli, F., Gotti, R., Guerrini, A., Carulli, G., Ottaviano, V., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021544 · Cited by 46
“In addition to multi-targeted therapeutics, multicomponent therapeutics is also proposed [4].”
BackgroundFrom protein interaction networks to novel therapeutic strategies
Jaeger, S., & Aloy, P. (2012) · IUBMB Life · doi:10.1002/iub.1040 · Cited by 43
“eases such as cancer, diabetes, and depression in a synergistic manner (78).”
BackgroundChloroquine–astemizole hybrids with potent in vitro and in vivo antiplasmodial activity
Musonda, C. C., Whitlock, G. A., Witty, M. J., Brun, R., & Kaiser, M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.11.047 · Cited by 44
A systematic analysis of signaling reactivation and drug resistance
Kholodenko, B. Ν., Rauch, N., Kölch, W., & Rukhlenko, O. S. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109157 · Cited by 44
“The efficiency of the ERK inhibition by a two-drug combination is comprehensively assessed by determining the ppERK response across a two-dimensional plane of drug doses (Keith et al., 2005; Yeh et al., 2009).”
BackgroundApoferritin Nanocage Delivers Combination of Microtubule and Nucleus Targeting Anticancer Drugs
Ghosh, S., Mohapatra, S., Thomas, A., Bhunia, D., Saha, A., Das, G., Jana, B., & Ghosh, S. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b11798 · Cited by 43
Liu, Q., Zhang, A., Wang, L., Yan, G., Zhao, H., Sun, H. J., Zou, S., Han, J., Ma, C. W., Kong, L. D., et al. (2016) · Scientific Reports · doi:10.1038/srep38437 · Cited by 44
Li, J., Olaleye, O. E., Yu, X., Jia, W., Yang, J., Lu, C., Liu, S., Yu, J., Duan, X.-N., Wang, Y., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.06.003 · Cited by 46
“Literature mining, comprising retrieval, extraction and review of information, was conducted to obtain three types of information: (1) antibiotics commonly used in management of sepsis and septic shock in China, (2) human pharmacokinetics/disposition of these antibiotics (particularly in critically ill patients), thei…”
BackgroundMethodAlsherbiny, M. A., Bhuyan, D. J., Radwan, I., Chang, D., & Li, C. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157840 · Cited by 46
“The combi‐ nation strategy may help overcome cancer complexity via targeting multiple pathophysi‐ ological components of the disease [32,33].”
BackgroundSystems biology, complexity, and the impact on antiepileptic drug discovery
Margineanu, D. G. (2013) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2013.08.029 · Cited by 45
“Consequently, instead of aiming a target-specific therapy, systems (or network) pharmacology seeks to correct a disturbed network via eithermultidrug therapies or multitargeted single drugs [20–22,29] (Fig.”
BackgroundDe, K., Li, X., Tang, G.-Y., & Zhang, H. (2007) · ChemMedChem · doi:10.1002/cmdc.200700291 · Cited by 45
Development of Oxadiazole-Sulfonamide-Based Compounds as Potential Antibacterial Agents
Ali, A., Hasan, P., Irfan, M. A., Uddin, A., Khan, A., Saraswat, J., Maguire, R., Kavanagh, K. A., Patel, R., Joshi, M. C., et al. (2021) · ACS Omega · doi:10.1021/acsomega.1c03379 · Cited by 42
Systems biology impact on antiepileptic drug discovery
Margineanu, D. G. (2011) · Epilepsy Research · doi:10.1016/j.eplepsyres.2011.10.006 · Cited by 46
Qi, J., Zhang, Y., Gou, Y., Lee, P., Wang, J., Chen, S., Zhou, Z., Wu, X., Yang, F., & Liang, H. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00277 · Cited by 43
Network Analysis as a Grand Unifier in Biomedical Data Science
McGillivray, P. D., Clarke, D., Meyerson, W. U., Zhang, J., Lee, D., Gu, M., Kumar, S., Zhou, H., & Gerstein, M. (2018) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-080917-013444 · Cited by 48
Neuropharmacology beyond reductionism – A likely prospect
Margineanu, D. G. (2015) · Biosystems · doi:10.1016/j.biosystems.2015.11.010 · Cited by 45
Obtaining and screening compound collections: a user's guide and a call to chemists
Hergenrother, P. J. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.04.005 · Cited by 46
“By explicitly screening combinations of compounds within the FDA-approved collection, several provocative discoveries were made, including a combination of a sedative (phenothiazine) and an anti-fungal (pentamidine) that together have anti-cancer activity [18].”
BackgroundNonlinear Blending: A Useful General Concept for the Assessment of Combination Drug Synergy
PETERSON, J. J., & NOVICK, S. J. (2007) · Journal of Receptors and Signal Transduction · doi:10.1080/10799890701417576 · Cited by 41
“Suppose that ED((1)) 50 = 1 and ED((2)) 50 = 3.”
BackgroundMethodInfluentialQuartararo, C. E., Reznik, E., deCarvalho, A. C., Mikkelsen, T., & Stockwell, B. R. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00128 · Cited by 43
Self-citationDrug repositioning for cancer in the era of AI, big omics, and real-world data
Wieder, R., & Adam, N. R. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103730 · Cited by 42
Cyclic nucleotide phosphodiesterases as drug targets
Kelly, M. P., Nikolaev, V. O., Gobejishvili, L., Lugnier, C., Heßlinger, C., Nickolaus, P., Kass, D. A., de Vasconcelos, W. P., Fischmeister, R., Brocke, S., et al. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100042 · Cited by 39
Synthesis of novel perillyl–dihydropyrimidinone hybrids designed for antiproliferative activity
Vendrusculo, V., de Souza, V. P., Fontoura, L. A. M., D’Oca, M. G. M., Banzato, T. P., Monteiro, P. A., Pilli, R. A., de Carvalho, J. E., & Russowsky, D. (2018) · MedChemComm · doi:10.1039/c8md00270c · Cited by 39
Radix Rehmanniae and Corni Fructus against Diabetic Nephropathy via AGE-RAGE Signaling Pathway
Chen, J., Chen, Y., Shu, A., Lu, J., Du, Q., Yang, Y., Lv, Z., & Xu, H. (2020) · Journal of Diabetes Research · doi:10.1155/2020/8358102 · Cited by 44
“This analysis of complex network is helpful to discover the relationship among multitarget drugs, drug combinations, and their signal pathways [14].”
BackgroundAnti-Tumour Efficacy of Capecitabine in a Genetically Engineered Mouse Model of Pancreatic Cancer
Courtin, A., Richards, F. M., Bapiro, T. E., Bramhall, J. L., Neeße, A., Cook, N., Krippendorff, B., Tuveson, D. A., & Jodrell, D. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067330 · Cited by 39
“The effect of the combination was evaluated using the Bliss Independance model [21,22] according to the protocol we have described previously [23].”
MethodReversing Hepatocellular Carcinoma Progression by Using Networked Biological Therapies
Epstein, R. J., & Leung, T. W. H. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1619 · Cited by 39
Networks from drug–drug surfaces
Yeh, P. J., & Kishony, R. (2007) · Molecular Systems Biology · doi:10.1038/msb4100133 · Cited by 42
“Multi-drug combinations are vital in modern medicine (Keith et al , 2005; Fitzgerald et al , 2006).”
Troubleshooting and deconvoluting label-free cell phenotypic assays in drug discovery
Ye, F. (2013) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2013.01.004 · Cited by 38
“…a promiscuous drug or a drug combination that simultaneously modulates multiple proteins in one process or parallel processes can be more efficacious for the treatment of complex disease (Boran & Iyengar, 2010; Kamb, Wee, & Lengauer, 2007; Keith et al., 2005; Schadt, Friend, & Shaywitz, 2009).”
BackgroundKoizumi, Y., & Iwami, S. (2014) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-11-41 · Cited by 40
“Research on biological network systems, as well as the biochemical characteristics of drugs, has also unraveled the mechanisms by which drug combinations produce synergistic effects (reviewed in [41,43-45]).”
BackgroundHelland, Ø., Popa, M. L., Bischof, K., Gjertsen, B. T., McCormack, E., & Bjørge, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158208 · Cited by 40
“Synergism was calculated by bliss independence analysis [36].”
BackgroundMethodCombined Cutaneous Therapy Using Biocompatible Metal-Organic Frameworks
Taherzade, S. D., Rojas, S., Soleimannejad, J., & Horcajada, P. (2020) · Nanomaterials · doi:10.3390/nano10122296 · Cited by 39
Harasym, T. O., Liboiron, B. D., & Mayer, L. D. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-416-6_13 · Cited by 39
Analysis of cancer signaling networks by systems biology to develop therapies
Prasasya, R. D., Tian, D., & Kreeger, P. K. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.04.001 · Cited by 37
Metadata
- Authors
- Keith, C. T., Borisy, A. A., & Stockwell, B. R.
- Affiliations
- Columbia University (US)
- Corresponding author
- Keith, Curtis T.
- Borisy, Alexis A.
- Stockwell, Brent R.
- ORCID
- Stockwell, Brent R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2005-01
- Volume
- 4
- Issue
- 1
- Pages
- 71-78
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1592483428
- Cited by
- 769
- References
- 67
- Citations by year
- 2026: 13 · 2025: 24 · 2024: 30 · 2023: 33 · 2022: 44 · 2021: 36 · 2020: 34 · 2019: 36 · 2018: 42 · 2017: 29 · 2016: 43 · 2015: 51 · 2014: 55 · 2013: 49 · 2012: 47
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Burroughs Wellcome Fund
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Keywords
- combination therapy, systems biology, mechanism of action, drug discovery
- MeSH terms
- Clinical Trials as Topic, Drug Synergism, Drug Therapy, Combination, Humans, Terminology as Topic, Drug Design
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.